Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305 203 2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

TruthBroker2 Nov. 21 at 11:57 AM

$SMMT

0 · Reply

HedgeAlerts Nov. 20 at 10:30 PM

Hedge Alert Live - Protect Your Portfolio Contract: $SMMT $16.00 Put · NOV 28, 2025 Exp Entry Price: $0.75 - $0.85 Exit Price Target: $1.19 Profit Margin: +59% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

RealStockTwitNewbie Nov. 20 at 9:53 PM

$SMMT The ”shell company” has 32 million+ shares that will need to be repaid suddenly, swiftly and without warning. Yikes. Any of them yours, Halbalideiya? 😩

0 · Reply

RealStockTwitNewbie Nov. 20 at 8:38 PM

$SMMT “Shorts only look comfortable on the surface — underneath, they’re sitting on a pressure cooker.”

1 · Reply

MoneyGroupLLC Nov. 20 at 6:32 PM

Enter: $SMMT Calls Strike Price: $18 Expiry Date: DEC 12 2025 Buy in Price: $1.33 - $2.25 Sell Price: $2.15 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

BigBeardTrader Nov. 20 at 6:30 PM

$SMMT I think Funds taking their gains before the end of the year is also playing into this. I think they're trying to get their bonuses and think the market is going to tank before EOY.

0 · Reply

letstalk8 Nov. 20 at 6:25 PM

$SMMT 6 weeks and counting when does it stop

0 · Reply

BigFishLittleBish Nov. 20 at 5:48 PM

$SMMT Just low volume and market downs.

0 · Reply

TruthBroker2 Nov. 20 at 5:44 PM

$SMMT Fuck

0 · Reply

Addallelectric Nov. 20 at 3:50 PM

$SMMT reloaded let’s gooo

0 · Reply

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 18, 2025, 12:38 PM EST - 2 days ago

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:11 AM EST - 10 days ago

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 9:00 AM EST - 13 days ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 4, 2025, 7:00 AM EST - 17 days ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 21 days ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 22, 2025, 8:00 AM EDT - 4 weeks ago

Summit Therapeutics Raises $500 Million in Private Placement

Oct 20, 2025, 5:05 PM EDT - 4 weeks ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 2:35 PM EDT - 4 weeks ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 10:05 AM EDT - 4 weeks ago

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 6:45 AM EDT - 4 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 19, 2025, 10:30 AM EDT - 4 weeks ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 17, 2025, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 15, 2025, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Sep 24, 2025, 4:30 PM EDT - 2 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 24, 2025, 7:00 AM EDT - 2 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 22, 2025, 2:45 PM EDT - 2 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Sep 17, 2025, 10:54 PM EDT - 2 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 16, 2025, 4:31 PM EDT - 2 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 2 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 9, 2025, 9:12 AM EDT - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Sep 8, 2025, 3:36 PM EDT - 2 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 8:28 AM EDT - 2 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:10 AM EDT - 2 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Sep 7, 2025, 6:08 AM EDT - 2 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 3:30 AM EDT - 2 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 3, 2025, 7:00 AM EDT - 2 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Aug 27, 2025, 2:43 PM EDT - 3 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 3 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 3 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 4 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 5 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 5, 2025, 8:00 AM EDT - 6 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 6 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 6 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 6 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 6 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 6 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 6:00 AM EDT - 6 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 2, 2025, 1:06 AM EDT - 7 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:20 PM EDT - 7 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

May 1, 2025, 4:09 PM EDT - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Apr 28, 2025, 1:00 PM EDT - 7 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 25, 2025, 3:14 PM EDT - 7 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 2:50 PM EDT - 7 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

TruthBroker2 Nov. 21 at 11:57 AM

$SMMT

0 · Reply

HedgeAlerts Nov. 20 at 10:30 PM

0 · Reply

RealStockTwitNewbie Nov. 20 at 9:53 PM

$SMMT The ”shell company” has 32 million+ shares that will need to be repaid suddenly, swiftly and without warning. Yikes. Any of them yours, Halbalideiya? 😩

0 · Reply

RealStockTwitNewbie Nov. 20 at 8:38 PM

$SMMT “Shorts only look comfortable on the surface — underneath, they’re sitting on a pressure cooker.”

1 · Reply

MoneyGroupLLC Nov. 20 at 6:32 PM

0 · Reply

BigBeardTrader Nov. 20 at 6:30 PM

$SMMT I think Funds taking their gains before the end of the year is also playing into this. I think they're trying to get their bonuses and think the market is going to tank before EOY.

0 · Reply

letstalk8 Nov. 20 at 6:25 PM

$SMMT 6 weeks and counting when does it stop

0 · Reply

BigFishLittleBish Nov. 20 at 5:48 PM

$SMMT Just low volume and market downs.

0 · Reply

TruthBroker2 Nov. 20 at 5:44 PM

$SMMT Fuck

0 · Reply

Addallelectric Nov. 20 at 3:50 PM

$SMMT reloaded let’s gooo

0 · Reply

RealStockTwitNewbie Nov. 20 at 1:31 PM

$SMMT “Price manipulation is like throwing rocks at a castle wall. It makes noise — but the castle doesn’t fall unless the foundation is weak. SMMT’s foundation is not weak.”

0 · Reply

TruthBroker2 Nov. 20 at 6:32 AM

$SMMT

0 · Reply

HedgeAlerts Nov. 20 at 6:32 AM

Hedge Alert Live - Protect Your Portfolio Contract: $SMMT $16.50 Put · NOV 28, 2025 Exp Entry Price: $1.01 - $1.06 Exit Price Target: $1.81 Profit Margin: +79% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

BigBeardTrader Nov. 19 at 10:50 PM

$SMMT my guess and it’s just that is 40-50 conservative. 80-90 if they expand into other cancers and prove it works.

0 · Reply

IIIlllllIlIIlIlI Nov. 19 at 10:21 PM

$SMMT wondering what the final price target is for this stock. Bought in recently, but realistically what's a reasonable price if everything goes well?

1 · Reply

LiquidThetaOptions Nov. 19 at 8:43 PM

💎 LiquidTheta® Live Actionable Trade Asset: $SMMT Contracts: $SMMT January 15, 2027 $18 Calls Scale in: $5.92- $7.23 Scale out: $23.01-$39.45 Profit Potential : 63% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HedgeAlerts Nov. 19 at 8:18 PM

Hedge Alert Live - Protect Your Portfolio Contract: $SMMT $16.00 Put · NOV 28, 2025 Exp Entry Price: $0.85 - $1.15 Exit Price Target: $1.87 Profit Margin: +120% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

BigBeardTrader Nov. 19 at 7:56 PM

$SMMT If you are a bull feeling shaken by the recent price action, here is my perspective. I have been holding since March 6, 2023 at 1 per share. I have added on the way up and down and now hold 16.5K shares and 215 LEAP contracts. I am not making predictions, only saying this: if I can hold, so can you. I am sure many others here can say the same. The main reason I am staying in is the quality of the management team. Good luck.

1 · Reply

TruthBroker2 Nov. 19 at 7:22 PM

$SMMT

0 · Reply

Halbalideiya Nov. 19 at 6:49 PM

$SMMT almost time for duggan and maky to prop this shell company up again

2 · Reply

letstalk8 Nov. 19 at 6:47 PM

$SMMT I have to buy here thank you lets load the boat!

0 · Reply

HitstheGreen Nov. 19 at 6:42 PM

$SMMT got more shares today

0 · Reply

Market Cap	12.77B
Revenue (ttm)	0.00
Net Income (ttm)	-221.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,700,200
Avg Vol	3,618,788
Day's Range	N/A - N/A
Shares Out	771.15M
Stochastic %K	16%
Beta	-1.21
Analysts	Strong Sell
Price Target	$32.31